In the long-term randomized EORTC 22922/10925 trial of 4,004 patients with stage I-III breast cancer, internal mammary and medial supraclavicular nodal irradiation lowered 20-year breast cancer-specific mortality to 18.6% vs 22.4% with standard radiotherapy alone. But after a median 22.2 years of follow-up, overall survival was essentially unchanged (61.0% vs 61.8%) because non-breast cancer deaths increased over time, as reported in CA: A Cancer Journal for Clinicians.

Why It Matters To Your Practice

• Regional nodal irradiation may reduce breast cancer deaths in selected early-stage patients with involved axillary nodes and/or centrally or medially located tumors.

• The survival tradeoff matters in primary care and oncology follow-up: long-term cardiopulmonary toxicity and competing mortality risks can offset cancer-specific gains.

• These findings reinforce the need for risk-adapted survivorship care over decades, not just the first 5 to 10 years.

Clinical Benefits

• Breast cancer-specific mortality was modestly lower with nodal irradiation: 18.6% vs 22.4% at 20 years.

• The authors described this as a nearly 20% relative reduction in breast cancer-related mortality.

• The benefit appeared over time, with early but slow separation of mortality curves beginning around 10 years and stabilizing after 15 years.

Managing Risks

• Overall survival was not improved: 61.0% with nodal irradiation vs 61.8% without it.

• Non-breast cancer mortality increased over time in the irradiated group, rising from a 0.1% excess at 10 years to 4.5% at 20 years.

• Watch for late cardiopulmonary effects, including cardiac disease and pulmonary fibrosis, when reviewing survivorship plans and symptoms.

• For NPs and PAs, this supports long-term monitoring of cardiovascular and pulmonary health after breast radiation, especially as patients age and comorbidities accumulate.

The Bottom Line

• Nodal irradiation can lower breast cancer-specific mortality, but it did not improve long-term overall survival in this trial.

• When counseling patients, balance recurrence and cancer mortality benefits against late toxicities, competing risks, and life expectancy.

• Tailored follow-up, patient education, and risk-adapted treatment decisions remain essential for long-term breast cancer survivors.